Sweden · Delayed Price · Currency is SEK Asker Healthcare Group AB Earnings Call Transcripts
Fiscal Year 2026
-
Strong Q1 performance with 13% sales growth and 21% adjusted EBITDA growth, driven by both organic expansion and accretive acquisitions. Margin improvement and robust cash flow support continued M&A, with stable leverage and positive outlook for 2026.
Fiscal Year 2025
-
Q4 saw 9% sales growth and a 16% rise in adjusted EBITA, with strong results in West and Central, and a 10% EBITDA margin achieved. Fourteen acquisitions expanded the footprint to 19 markets, and leverage remains stable, supporting continued M&A and a proposed 30% dividend.
-
Q3 saw 25% earnings growth and 15% sales growth, with strong results in West and Central, and a robust M&A pipeline. Leverage remains within target, and underlying organic growth is solid across regions, despite lumpy defense sales in North.
-
Q2 saw 12% adjusted EBITDA growth (after FX), 9% sales growth, and a 9.5% EBITDA margin, with strong M&A activity and a robust pipeline. Region West and Central delivered strong results, while North faced headwinds from lower project-based sales.
-
Q1 delivered 16% sales and 17% adjusted EBITDA growth, with strong organic and M&A contributions. The IPO strengthened the balance sheet, enabling continued acquisition activity, while margins and key metrics improved toward targets.